Login to Your Account

NewCo News

Galecto Targeting Galectin-3 Via Small-Molecule Approach

By Cormac Sheridan
Staff Writer

Wednesday, April 25, 2012
Newly formed Galecto Biotech AB is taking a distinctive approach to inhibiting galectin-3, a newly emerging target in several disease areas, and to tackling idiopathic pulmonary fibrosis (IPF) as its lead indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription